Current analgesic approach for water vapor therapy is transrectal periprostatic block (PNB) or general sedation. PNB is uncomfortable and holds a risk of infection. Sedation poses safety risks and presence of an anesthesiology team.

Use of transurethral intraprostatic anesthesia (TUIA) using Schelin Catheter provides a non-invasive, efficient technique for out-patient, office-based procedures.

both studies that were presented; “Multicenter study evaluating the safety and feasibility of Transurethral Intraprostatic Injections of Anesthetics (TUIA) delivered via an innovative catheter to perform minimally invasive surgical techniques for benign prostatic obstructions” by Dr Secco and co-authors and “Transurethral Intraprostatic Injections of Anesthetics (TUIA) and cortisone before rezum treatment shows full pain control and it improves post-operative dysuria” by Dr Siena and co-authors, concludes that TUIA with the Schelin Catheter is a simple technique that shows full pain control before water vapor therapy.

TUIA with Schelin Catheter enhances the treatment and optimizes the need for equipment and set-up. Moreover, adding cortisone to the anesthetics showed a significant reduction of dysuria and catheter discomfort compared to standard general anesthesia and TUIA with only anesthetics.

“We are delighted to see more independent clinical studies on our Schelin Catheter. We are pleased being able offering this unique device for the urological community, enhancing the treatment from different perspectives for both professionals and patients.” says Anders Kristensson, CEO of ProstaLund.